|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
3.29/5.29
|
Enterprise Value
212.12B
|
Balance Sheet |
Book Value Per Share
22.94
|
Cash Flow |
Cash Flow Yield
0.04
|
Income Statement |
Total Revenue
40.11B
|
Operating Revenue Per Share
23.04
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/01/21 02:12 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States. |